Lexeo Therapeutics
Logotype for Lexeo Therapeutics Inc

Lexeo Therapeutics (LXEO) investor relations material

Lexeo Therapeutics Q3 2026 & Study result earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Lexeo Therapeutics Inc
Q3 2026 & Study result earnings summary16 Nov, 2026

Executive summary

  • HEROIC-PKP2 interim data across 10 participants showed reduced arrhythmia burden and potential improvement in cardiac function; LX2020 was generally well tolerated.

  • High-dose participants had mean reductions of 80% in NSVT burden and 44% in PVC burden at latest assessment; five of seven reported symptom improvement.

  • FDA is open to guideline-defined NSVT as a primary surrogate endpoint for a potential accelerated-approval study.

  • Q3 net loss was $38.3M; cash, cash equivalents and Treasury investments totaled $219.1M at September 30, with runway expected into 2028.

Financial highlights

  • Q3 revenue was $0; operating expenses were $40.4M versus $21.6M, and net loss was $38.3M versus $20.3M year over year.

  • Q3 R&D was $34.5M versus $15.7M; the increase largely reflected Mantle acquisition costs and an LX2006 milestone. G&A was $5.9M versus $6.0M.

  • 9M operating expenses were $90.8M versus $86.1M; net loss was $84.4M versus $79.0M, including $9.9M of acquired IPR&D expense in 2026.

  • 9M R&D was $69.2M versus $47.6M; G&A was $21.5M versus $38.6M.

Outlook and guidance

  • LX2020 pivotal-study initiation is targeted for H2 2027, with estimated enrollment of 60–80 participants and NSVT as the proposed primary surrogate endpoint.

  • Proposed accelerated-approval analysis would assess the proportion of patients below one NSVT episode per day at 12 months.

  • FDA discussions on study design, statistical analysis and confirmatory evidence are expected to continue into H1 2027; a controlled design is considered feasible.

  • Cash, cash equivalents and investments are expected to fund planned operations into 2028; spending is expected to rise as trials and capabilities advance.

  • Longer-term follow-up is intended to assess clinical endpoints for potential full approval, including PVC burden and ICD events.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Lexeo Therapeutics earnings date

Logotype for Lexeo Therapeutics Inc
Q4 202612 Mar, 2027
Lexeo Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Lexeo Therapeutics earnings date

Logotype for Lexeo Therapeutics Inc
Q4 202612 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Lexeo Therapeutics Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company is advancing a portfolio of gene therapy candidates, including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. Additionally, Lexeo Therapeutics is developing therapies for APOE4 homozygous conditions and CLN2 Batten disease, among others, utilizing its AAVrh10-based gene therapy platform. The company is headquartered in New York, New York, and its shares are listed on the Nasdaq.